Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...
Register today at no cost to our Explorer Insights subscription and access more of the TGS | 4C database and additional functionality such as tailored notifications, enhanced search capabilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback